Literature DB >> 23428112

Does warfarin use impact hospital length of stay? A retrospective study looking at patients treated for atrial fibrillation.

Nicole Mittmann1, Blair Henry, Shahryar Murshed, Laura Tsang, John Iazzetta, Eugene Crystal, Claudia Bucci.   

Abstract

The authors received anecdotal practice information from clinicians indicating that when warfarin was initiated in the hospital setting, it may be associated with an increased length of stay (LOS): specifically to achieve a desired minimum international normalized ratio (INR) of 2.0 before discharge in a subset of patients where clinicians perceived follow-up after discharge was not deemed optimal. Given that oral thromboprophylactic anticoagulation with warfarin is the mainstay treatment for the prevention of stroke in atrial fibrillation (AF), the authors decided to look at hospitalized patients from this population to determine if a subset of these patients experienced an increased LOS. The study design entailed a retrospective chart review of consecutive patients admitted to a large, tertiary care, academic center. Patients were included if they were admitted with a primary, secondary, or most responsible diagnosis of paroxysmal or chronic AF. Medical records were audited over an 18-month period (February 1, 2009, to July 31, 2010) to determine the average LOS and to identify patients with a documented prolonged LOS secondary due to subtherapeutic INR at the time of potential discharge. Our final study cohort of 189 patients had an average LOS of 5.2 days (SD = 5.2). However, for eight (4.2%) of these patients discharge was delayed an additional 2.25 days (SD = 1.3) for reasons solely attributed to achieving a therapeutic INR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23428112     DOI: 10.1080/00185868.2013.757969

Source DB:  PubMed          Journal:  Hosp Top        ISSN: 0018-5868


  1 in total

1.  GPs' adherence to guidelines for structured assessments of stroke survivors in the community and care homes.

Authors:  Daniela C Gonçalves-Bradley; Anne-Marie Boylan; Constantinos Koshiaris; Maria Vazquez Montes; Gary A Ford; Daniel S Lasserson
Journal:  Fam Pract       Date:  2015-09-30       Impact factor: 2.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.